COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,864 Articles (22,568 medRxiv, 8,296 bioRxiv)

Most recent first Previous |  Page 1878: Articles 18771-18780  | Next

RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2
Verma, R., Saha, S., Kumar, S., Mani, S., Maiti, T. K., Surjit, M.
10.1101/2021.01.05.425516 — Posted: 2021-01-06
COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes
Jenner, A. L., Aogo, R. A., Alfonso, S., Crowe, V., Smith, A. P., Morel, P. A., Davis, C. L., Smith, A. M., Craig, M.
10.1101/2021.01.05.425420 — Posted: 2021-01-06
Human cell-dependent, directional, time-dependent changes in the mono- and oligonucleotide compositions of SARS-CoV-2 genomes
Iwasaki, Y., Abe, T., Ikemura, T.
10.1101/2021.01.05.425508 — Posted: 2021-01-06
Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients
Olea, B., Vicent, E. A., Torres, I., Amat, P., Remigia, M. J., Gozalbo, R., Rodriguez, J., Buesa, J., Blasco, M. L., Redon, J., Signes, J., Navarro, D.
10.1101/2021.01.05.20249027 — Posted: 2021-01-06
Modelling Decay of Population Immunity With Proposed Second Dose Deferral Strategy
Jurgens, G. T.
10.1101/2021.01.05.21249293 — Posted: 2021-01-06 Discussion: Onsite
Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.
Babalola, O. E., Bode, C. O., Ajayi, A. A., Alakaloko, F. M., Akase, I. E., Otrofanowei, E., Salu, O. B., Adeyemo, W. L., Ademuyiwa, A. O., Omilabu, S. A.
10.1101/2021.01.05.21249131 — Posted: 2021-01-06 Discussion: Onsite
Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated temperatures
Haage, V. C., Ferreira de Oliveira-Filho, E., Moreira-Soto, A., Kühne, A., Fischer, C., Sacks, J., Corman, V. M., Müller, M. A., Drosten, C., Drexler, J. F.
10.1101/2021.01.06.21249314 — Posted: 2021-01-06
Fever, Diarrhea, and Severe Disease Correlate with High Persistent Antibody Levels against SARS-CoV-2
Amjadi, M. F., O'Connell, S. E., Armbrust, T., Mergaert, A. M., Narpala, S. R., Halfmann, P. J., Bashar, S. J., Glover, C. R., Heffron, A. S., Taylor, A., Flach, B., O'Connor, D. H., Kawaoka, Y., McDermott, A. B., Sethi, A. K., Shelef, M. A.
10.1101/2021.01.05.21249240 — Posted: 2021-01-06
THE INTESTINAL AND ORAL MICROBIOMES ARE ROBUST PREDICTORS OF COVID-19 SEVERITY THE MAIN PREDICTOR OF COVID-19-RELATED FATALITY
Ward, D. V., Bhattarai, S., Rojas-Correa, M., Purkayastha, A., Holler, D., Qu, M. D., Mitchell, W. G., Yang, J., Fountain, S., Zeamer, A., Forconi, C., Fujimori, G., Odwar, B., Cawley, C., McCormick, B. A., Moormann, A., Wessolossky, M., Bucci, V., Maldonado-Contreras, A.
10.1101/2021.01.05.20249061 — Posted: 2021-01-06
Long term impact on lung function of patients with moderate and severe COVID-19. A prospective cohort study
Qureshi, S., Nasir, N., Rashid, N., Ahmed, N., Haq, Z., Qamar, F. N.
10.1101/2021.01.06.21249312 — Posted: 2021-01-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).